New research to deliver cancer-killing viruses to tumour cells
![](/46/pdcnewsitem/03/63/20/against%20breast%20cancer.gif)
Oxford scientists announce laboratory success using a new linker technique to bond cell-killing agents to cancer-targeting antibodies
Scientists at the University of Oxford have invented a new linker to attach a cancer-killing virus to a tumour-targeting antibody, in research published in the scientific journal Molecular Immunology.
The new linker is built of molecular human components and is designed to bond a cell-killing virus to an antibody directed against a target cell, such as cancerous cell. Against Breast Cancer, who funded some of the research, hope that this method could be used to destroy secondary breast cancer cells that have trafficked from the breast to other parts of the body, namely the bone, liver, lung or brain.
Iona Easthope who performed some of the research says: “We were excited to see that this linker connected a virus to the breast-cancer cell-targeting antibody in a stable manner at 37 degrees, as well as successfully re-targeting the viruses to enter breast cancer cells without affecting the healthy cells.”
The re-targeting adaptor linker is an improvement on a similar product made up of bacterial components, which were recognized by the body as a threat and broken down before the treatment could be allowed to reach target cells and take effect.
Dr Max Crispin was the one of the lead investigators on the project. “Humanized bispecific adaptors offer the promise of a versatile retargeting technology that can exploit both clinically approved and new experimental therapeutic antibodies for cancer and other diseases. We have dedicated this research article to Dr Chris Scanlan who started this project and sadly passed away after a short battle with cancer.”
One in five breast cancer cases result in fatal metastases, when breast cancer cells break away from the original tumour site and establish new tumours in bone, lung, liver or brain. The new linker could pave the way for better, more targeted treatment methods for many types of cancer, including Stage IV secondary cancers that have spread throughout the body.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance